472 related articles for article (PubMed ID: 16129210)
1. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
4. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Crawford J; Cella D; Cleeland CS; Cremieux PY; Demetri GD; Sarokhan BJ; Slavin MB; Glaspy JA
Cancer; 2002 Aug; 95(4):888-95. PubMed ID: 12209734
[TBL] [Abstract][Full Text] [Related]
5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
6. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
7. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
8. Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003.
Solid CA; Foley RN; Gilbertson DT; Collins AJ
Hemodial Int; 2007 Oct; 11(4):442-7. PubMed ID: 17922742
[TBL] [Abstract][Full Text] [Related]
9. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
13. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
14. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
15. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
[TBL] [Abstract][Full Text] [Related]
16. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
18. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
Chan K; Moran J; Hlatky M; Lafayette R
Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
[TBL] [Abstract][Full Text] [Related]
19. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
20. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
